Ovarian cancer is the fifth leading cause of cancer-related deaths among U.S. women and is regarded ...
Nektar's Drug Could be a "Big Deal"
06/21/2019 5:00 am EST
Nektar (NKTR) has a drug called NKTR-358 and they presented data from a clinical trial at EULAR (European League Against Rheumatism); in short NKTR-358 could be a very big deal, explains small cap expert Tom Bishop, editor of BI Research.
It is a “novel IL-2 conjugate of a T-reg simulator.” IL-2 is interlukin-2, which is a stimulator of T- cells and in particular T-reg cells. T-reg cells are regulator T-cells that keep “effector” T-cells from attacking normal tissue, as occurs in auto-immune diseases like lupus (SLE) and rheumatoid arthritis and a host of auto-immune diseases.
Auto-immune disease are when the body’s built in defenses (T-cells) attack good tissue instead of just the foreign invasions they normally fend off.
T-reg cells normally keep those effector T-cells (which we all have, and need) in check. However when the T-reg cells’ influence becomes weak, the body (the effector T-cells) can turn on itself and we can get one of a host of auto-immune diseases.
So, NKTR-358 is a form of IL-2 (but not just straight up IL-2 which has limitations like a 1-hour half-life vs. 8-9 days for NKTR-358 and that IL-2 will stimulate all T-cell growth not just T-regs) that stimulates the T-reg cells to multiply and be more effective in doing their job of keeping the effector T cells from turning on the body that they were actually designed to protect from foreign intrusions (don’t attack the host guys!).
NKTR-358 which employs a low dose IL-2 conjugate has been proven in this recently reported clinical trial in healthy humans to be safe and to selectively activate T-regs without stimulating the out of control effector T-cells.
Accordingly the company has already advanced NKTR-358 into a clinical trial in lupus (SLE) patients, with trials on four more auto-immune diseases now in the planning stages and likely to be announced before year end. NKTR-358 is expected to be taken chronically, though later on likely at maintenance doses.
NKTR-358 is being developed in partnership with Eli Lilly (LLY). Due to its mechanism of action it could, as with cancer fighting drug NKTR-214, find its way into combination therapies with other companies’ drugs.
Indeed it has already been tested with cyclosporine pre-clinically to great success. So lots of blue sky and promise here ... as if we needed more on top of that for NKTR-181 and NKTR-214. The shares, which have traded over $100, remain a Buy here under $40.
Related Articles on HEALTHCARE
Viemed Healthcare (VMD), through its wholly owned subsidiaries Sleep Management and Home Sleep, is a...
Zoetis (ZTS) is among the top global companies in the discovery, development, manufacture, and marke...
The pandemic driven recession isn’t even a speed bump for AbbVie (ABBV), a biopharmaceutical g...